JP2023501453A5 - - Google Patents
Info
- Publication number
- JP2023501453A5 JP2023501453A5 JP2022526496A JP2022526496A JP2023501453A5 JP 2023501453 A5 JP2023501453 A5 JP 2023501453A5 JP 2022526496 A JP2022526496 A JP 2022526496A JP 2022526496 A JP2022526496 A JP 2022526496A JP 2023501453 A5 JP2023501453 A5 JP 2023501453A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- subject
- week
- treatment
- srt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933517P | 2019-11-10 | 2019-11-10 | |
| US62/933,517 | 2019-11-10 | ||
| US201962933970P | 2019-11-11 | 2019-11-11 | |
| US62/933,970 | 2019-11-11 | ||
| US201962935922P | 2019-11-15 | 2019-11-15 | |
| US62/935,922 | 2019-11-15 | ||
| US202063001473P | 2020-03-29 | 2020-03-29 | |
| US63/001,473 | 2020-03-29 | ||
| US202063002302P | 2020-03-30 | 2020-03-30 | |
| US63/002,302 | 2020-03-30 | ||
| US202063006701P | 2020-04-07 | 2020-04-07 | |
| US63/006,701 | 2020-04-07 | ||
| US202063022573P | 2020-05-10 | 2020-05-10 | |
| US63/022,573 | 2020-05-10 | ||
| US202063059143P | 2020-07-30 | 2020-07-30 | |
| US63/059,143 | 2020-07-30 | ||
| US202063064450P | 2020-08-12 | 2020-08-12 | |
| US63/064,450 | 2020-08-12 | ||
| PCT/US2020/059893 WO2021092598A1 (en) | 2019-11-10 | 2020-11-10 | Methods of treatment with myosin modulator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023501453A JP2023501453A (ja) | 2023-01-18 |
| JP2023501453A5 true JP2023501453A5 (https=) | 2024-01-09 |
| JP7830321B2 JP7830321B2 (ja) | 2026-03-16 |
Family
ID=75849342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526496A Active JP7830321B2 (ja) | 2019-11-10 | 2020-11-10 | ミオシンモジュレーターによる治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230158027A1 (https=) |
| EP (1) | EP4054588A4 (https=) |
| JP (1) | JP7830321B2 (https=) |
| KR (1) | KR20220113387A (https=) |
| CN (1) | CN114945372A (https=) |
| AU (1) | AU2020378197A1 (https=) |
| BR (1) | BR112022008641A2 (https=) |
| CA (1) | CA3157629A1 (https=) |
| CL (1) | CL2022001217A1 (https=) |
| IL (1) | IL292840A (https=) |
| MX (1) | MX2022005465A (https=) |
| TW (1) | TW202134259A (https=) |
| WO (1) | WO2021092598A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3645002T3 (da) | 2017-06-30 | 2024-12-16 | Amgen Inc | Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| HUE069154T2 (hu) * | 2020-01-28 | 2025-02-28 | Assia Chem Ind Ltd | A mavakamten szilárd állapotú formái és eljárás elõállításukra |
| MX2023002024A (es) * | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| DK4243825T3 (da) | 2020-11-12 | 2025-12-01 | Amgen Inc | Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper |
| CN115461052B (zh) * | 2020-11-25 | 2023-12-22 | 深圳信立泰药业股份有限公司 | Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途 |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| CN112939876A (zh) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (en) * | 2021-03-12 | 2022-09-15 | Sandoz Ag | Crystalline forms of mavacamten for the treatment of hcm |
| PT4370116T (pt) * | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| WO2023102452A1 (en) * | 2021-12-02 | 2023-06-08 | Tenax Therapeutics, Inc. | Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure |
| CN116410143A (zh) * | 2021-12-29 | 2023-07-11 | 杭州奥默医药股份有限公司 | 一种多取代脲嘧啶衍生物及其制备方法和应用 |
| CA3248508A1 (en) | 2022-04-13 | 2023-10-19 | Assia Chemical Industries Ltd. | SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD |
| EP4514355A1 (en) * | 2022-04-26 | 2025-03-05 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
| JP2025534288A (ja) | 2022-09-26 | 2025-10-15 | エッジワイズ セラピューティクス， インコーポレイテッド | １，４－ジヒドロキナゾリノン化合物およびその使用 |
| WO2024097284A1 (en) * | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
| WO2024206339A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
| IT202300016653A1 (it) | 2023-08-03 | 2025-02-03 | Olon Spa | Processo per preparare mavacamten e intermedio di processo. |
| WO2025046606A1 (en) | 2023-08-26 | 2025-03-06 | Micro Labs Limited | Granules of mavacamten for oral administration |
| WO2025096779A2 (en) * | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0908193D0 (en) * | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| EP3399907A4 (en) * | 2016-01-04 | 2019-08-28 | Aventusoft, LLC | SYSTEM AND METHOD FOR MEASURING HEMODYNAMIC PARAMETERS FROM THE HEADLAPPING SIGNALS |
| CA3071948A1 (en) * | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
-
2020
- 2020-11-10 EP EP20884325.0A patent/EP4054588A4/en active Pending
- 2020-11-10 MX MX2022005465A patent/MX2022005465A/es unknown
- 2020-11-10 TW TW109139230A patent/TW202134259A/zh unknown
- 2020-11-10 AU AU2020378197A patent/AU2020378197A1/en active Pending
- 2020-11-10 CA CA3157629A patent/CA3157629A1/en active Pending
- 2020-11-10 JP JP2022526496A patent/JP7830321B2/ja active Active
- 2020-11-10 CN CN202080092267.1A patent/CN114945372A/zh active Pending
- 2020-11-10 KR KR1020227019428A patent/KR20220113387A/ko active Pending
- 2020-11-10 WO PCT/US2020/059893 patent/WO2021092598A1/en not_active Ceased
- 2020-11-10 BR BR112022008641A patent/BR112022008641A2/pt unknown
- 2020-11-10 US US17/775,375 patent/US20230158027A1/en active Pending
-
2022
- 2022-05-08 IL IL292840A patent/IL292840A/en unknown
- 2022-05-10 CL CL2022001217A patent/CL2022001217A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501453A5 (https=) | ||
| Schindler et al. | Exercise in heart failure—what is the optimal dose to improve pathophysiology and exercise capacity? | |
| JP2024526334A5 (https=) | ||
| Tanriverdi et al. | Effects of high intensity interval-based inspiratory muscle training in patients with heart failure: A single-blind randomized controlled trial | |
| Cetin et al. | Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results, Cardiovascular Journal of Africa 25 (4) 2014: pp. 168-175 | |
| Aten et al. | Dressler syndrome: not just a relic of the past | |
| JP2013544870A (ja) | 肝障害のリスク管理に使用する薬剤の調製のためのドロネダロンの使用 | |
| Zain et al. | Epicardial adipose tissue and development of atrial fibrillation (AFIB) and heart failure with preserved ejection fraction (HFpEF) | |
| Baffa et al. | Noninvasive ventilation can modulate heart rate variability during high-intensity exercise in COPD-CHF patients | |
| Momomura et al. | Efficacy and safety of switching from oral bisoprolol to transdermal patch in Japanese patients with chronic heart failure | |
| Wasada et al. | Association of sick sinus syndrome with hyperinsulinemia and insulin resistance in patients with non-insulin-dependent diabetes mellitus: report of four cases | |
| WO2024255256A1 (zh) | 丙酮酸脱氢酶激酶抑制剂在治疗射血分数保留型心力衰竭中的应用 | |
| Tada et al. | Progression from exercise-induced to resting left atrial hypertension in HFpEF: impact of reduced atriopulmonary compliance | |
| JP2025513337A (ja) | 心原性ショック前および心原性ショックの処置のためのイスタロキシムを含む静脈内注入製剤 | |
| Wang et al. | Clinical outcomes of cardiac shockwave therapy in severe coronary artery disease patients after coronary artery bypass grafting | |
| Fernández-Ruiz | Semaglutide is beneficial in patients with HFpEF and obesity | |
| JP2025513337A5 (https=) | ||
| Cordero et al. | Hiccups: nerve irritation or masquerading as acute coronary syndrome | |
| To et al. | A broken heart after witnessing a dying heart: a case of takotsubo cardiomyopathy | |
| Vlachogeorgos et al. | Bosentan for patients with echocardiographic evidence of pulmonary hypertension due to long-standing rheumatic mitral stenosis | |
| Korkmaz et al. | The effects of levosimendan use on high-sensitivity C-reactive protein in patients with decompensated heart failure | |
| Labarta-Bello et al. | Severe Pectus Excavatum: Unusual Cause of Sudden Cardiac Death Linked to a Novel Genetic Variant | |
| Davtyan et al. | Antithrombotic therapy in patients with non-valvular atrial fibrillation and high risk of stroke after successful endovascular left atrial appendage occlusion | |
| Jaworska-Wilczyńska et al. | Post-cardiac injury syndrome | |
| Jung et al. | Selexipag as add-on therapy for patients with pulmonary arterial hypertension associated with congenital heart disease: a single-center retrospective study |